article

Stem Cells In-Depth Focus 2018

Posted: 31 May 2018 | | No comments yet

In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.

Stem cells in-depth focus #2 2018
  • Urine-derived stem cells as innovative platform for drug testing and disease modelling
    Urine-derived stem cells offer an innovative platform for drug testing and disease modelling, writes Lucas-Sebastian Spitzhorn, Shaifur Rahman, Lisa Nguyen, Audrey Ncube, Martina Bohndorf, Wasco Wruck and James Adjaye.
  • From fibroblasts to medicinal signalling cells: a paradigm shift in translational stem cell research
    There’s been a paradigm shift in translational stem cell research from fibroblasts to medicinal signalling cells, according to Jonathan Sheard, Thamil Selvee Ramasamy and Darius Widera.
  • The role of biomaterials in stem cell-based regenerative medicine
    Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success, claims Laura Goldie.

This In-Depth Focus is restricted - login or subscribe free to access

Drug Target Review issue 4 2018 coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 


Send this to a friend